Literature DB >> 18319271

Distribution and expression of soluble epoxide hydrolase in human brain.

Priyanka Sura1, Radhakrishna Sura, Ahmed E Enayetallah, David F Grant.   

Abstract

Epoxyeicosatrienoic acids (EETs) are cytochrome P450 metabolites of arachidonic acid, which function in the brain to regulate cerebral blood flow and protect against ischemic brain injury. EETs are converted by soluble epoxide hydrolase (sEH) to the corresponding inactive diol metabolites. Previous animal studies have indicated that sEH gene deletion or treatment with sEH inhibitors results in increased levels of EETs and protection against stroke-induced brain damage. To begin elucidating the underlying mechanism for these effects, we sought to determine the distribution, expression, and activity of sEH in human brain samples obtained from patients with no neurological changes/pathologies. Immunohistochemical analyses showed the distribution of sEH mainly in the neuronal cell bodies, oligodendrocytes, and scattered astrocytes. Surprisingly, in the choroid plexus, sEH was found to be highly expressed in ependymal cells. Vascular localization of sEH was evident in several regions, where it was highly expressed in the smooth muscles of the arterioles. Western blot analysis and enzyme assays confirmed the presence of sEH in the normal brain. Our results indicate differential localization of sEH in the human brain, thus suggestive of an essential role for this enzyme in the central nervous system. This manuscript contains online supplemental material at http://www.jhc.org. Please visit this article online to view these materials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18319271      PMCID: PMC2386770          DOI: 10.1369/jhc.2008.950659

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  38 in total

Review 1.  Epoxygenase pathways of arachidonic acid metabolism.

Authors:  D C Zeldin
Journal:  J Biol Chem       Date:  2001-07-12       Impact factor: 5.157

2.  Suppression of cortical functional hyperemia to vibrissal stimulation in the rat by epoxygenase inhibitors.

Authors:  Xinqi Peng; Juan R Carhuapoma; Anish Bhardwaj; Nabil J Alkayed; John R Falck; David R Harder; Richard J Traystman; Raymond C Koehler
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-11       Impact factor: 4.733

3.  Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids.

Authors:  Jianxin Sun; XinXin Sui; J Alyce Bradbury; Darryl C Zeldin; Michael S Conte; James K Liao
Journal:  Circ Res       Date:  2002-05-17       Impact factor: 17.367

Review 4.  P-450 metabolites of arachidonic acid in the control of cardiovascular function.

Authors:  Richard J Roman
Journal:  Physiol Rev       Date:  2002-01       Impact factor: 37.312

5.  Identification and functional characterization of human soluble epoxide hydrolase genetic polymorphisms.

Authors:  M Sandberg; C Hassett; E T Adman; J Meijer; C J Omiecinski
Journal:  J Biol Chem       Date:  2000-09-15       Impact factor: 5.157

6.  The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase.

Authors:  Annette Cronin; Sherry Mowbray; Heike Dürk; Shirli Homburg; Ingrid Fleming; Beate Fisslthaler; Franz Oesch; Michael Arand
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

7.  The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity.

Authors:  John W Newman; Christophe Morisseau; Todd R Harris; Bruce D Hammock
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-06       Impact factor: 11.205

8.  Polymorphisms in human soluble epoxide hydrolase.

Authors:  Beata D Przybyla-Zawislak; Punit K Srivastava; Johana Vazquez-Matias; Harvey W Mohrenweiser; Joseph E Maxwell; Bruce D Hammock; J Alyce Bradbury; Ahmed E Enayetallah; Darryl C Zeldin; David F Grant
Journal:  Mol Pharmacol       Date:  2003-08       Impact factor: 4.436

Review 9.  Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function.

Authors:  Arthur A Spector; Xiang Fang; Gary D Snyder; Neal L Weintraub
Journal:  Prog Lipid Res       Date:  2004-01       Impact factor: 16.195

10.  Soluble epoxide hydrolase: a novel therapeutic target in stroke.

Authors:  Wenri Zhang; Ines P Koerner; Ruediger Noppens; Marjorie Grafe; Hsing-Ju Tsai; Christophe Morisseau; Ayala Luria; Bruce D Hammock; John R Falck; Nabil J Alkayed
Journal:  J Cereb Blood Flow Metab       Date:  2007-04-18       Impact factor: 6.200

View more
  51 in total

1.  Soluble epoxide hydrolase inhibition provides multi-target therapeutic effects in rats after spinal cord injury.

Authors:  Xiaojing Chen; Xiaoqi Chen; Xiaojiang Huang; Chuan Qin; Yongkang Fang; Yang Liu; Guibing Zhang; Dengji Pan; Wei Wang; Minjie Xie
Journal:  Mol Neurobiol       Date:  2015-02-10       Impact factor: 5.590

Review 2.  Humble beginnings with big goals: Small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders.

Authors:  Sydney Zarriello; Julian P Tuazon; Sydney Corey; Samantha Schimmel; Mira Rajani; Anna Gorsky; Diego Incontri; Bruce D Hammock; Cesar V Borlongan
Journal:  Prog Neurobiol       Date:  2018-11-14       Impact factor: 11.685

3.  Therapeutic activity of inhibition of the soluble epoxide hydrolase in a mouse model of scrapie.

Authors:  Giorgio Poli; Erica Corda; Piera Anna Martino; Paola Dall'ara; Silvio R Bareggi; Giampietro Bondiolotti; Barbara Iulini; Maria Mazza; Cristina Casalone; Sung Hee Hwang; Bruce D Hammock; Bora Inceoglu
Journal:  Life Sci       Date:  2013-05-05       Impact factor: 5.037

4.  Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism.

Authors:  Xiaocui Qin; Qiaoqi Wu; Lifang Lin; Aimin Sun; Shuhu Liu; Xiaowen Li; Xiong Cao; Tianming Gao; Pengcheng Luo; Xinhong Zhu; Xuemin Wang
Journal:  Mol Neurobiol       Date:  2014-08-17       Impact factor: 5.590

5.  Role of soluble epoxide hydrolase in age-related vascular cognitive decline.

Authors:  Jonathan W Nelson; Jennifer M Young; Rohan N Borkar; Randy L Woltjer; Joseph F Quinn; Lisa C Silbert; Marjorie R Grafe; Nabil J Alkayed
Journal:  Prostaglandins Other Lipid Mediat       Date:  2014-09-30       Impact factor: 3.072

Review 6.  Reconceptualization of translocator protein as a biomarker of neuroinflammation in psychiatry.

Authors:  T Notter; J M Coughlin; A Sawa; U Meyer
Journal:  Mol Psychiatry       Date:  2017-12-05       Impact factor: 15.992

Review 7.  Cytochrome P450 derived epoxidized fatty acids as a therapeutic tool against neuroinflammatory diseases.

Authors:  Jogen Atone; Karen Wagner; Kenji Hashimoto; Bruce D Hammock
Journal:  Prostaglandins Other Lipid Mediat       Date:  2019-11-05       Impact factor: 3.072

8.  A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist.

Authors:  Natasha T Snider; James A Nast; Laura A Tesmer; Paul F Hollenberg
Journal:  Mol Pharmacol       Date:  2009-01-26       Impact factor: 4.436

9.  Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent.

Authors:  Jeffrey J Iliff; Nabil J Alkayed
Journal:  Future Neurol       Date:  2009-03-01

Review 10.  Soluble epoxide hydrolase: gene structure, expression and deletion.

Authors:  Todd R Harris; Bruce D Hammock
Journal:  Gene       Date:  2013-05-20       Impact factor: 3.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.